Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin

Annals of Neurology

Volumn 74, Issue 2, 2013, Pages 266-274

  Mazya, Michael V ^a   Lees, Kennedy R ^b   Markus, Romesh ^c   Roine, Risto O ^d   Seet, Raymond C S ^e   Wahlgren, Nils ^a   Ahmed, Niaz ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c ST VINCENT S HOSPITAL   (Australia)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; WARFARIN;

AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY; MORTALITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYMPTOMATIC INTRACEREBRAL HEMORRHAGE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); REGISTRIES; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; WARFARIN;

EID: 84884901338     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23924     Document Type: Article

References (29)

1. Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with acute ischemic stroke. Stroke 2007; 38: 1655-1711.
2. European Agency for the Evaluation of Medicinal Products. Actilyse. Available at: http://www.emea.europa.eu/docs/en-GB/document-library/Referrals- document/Actilyse-29/WC500010327.pdf Accessed June 6, 2012.
3. European Stroke Organization (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507.
4. Xian Y, Liang L, Smith EE, et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 2012; 307: 2600-2608.
5. Kim YD, Lee JH, Jung YH, et al. Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use. J Neurol Sci 2010; 298: 101-105.
6. Seet CS, Zhang Y, Moore A, et al. Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke 2011; 42: 2333-2335.
7. Ibrahim MM, Sebastian J, Hussain M, et al. Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke? Cerebrovasc Dis 2010; 30: 508-513.
8. Levin D, Smith DB, Cumbler E, et al. Warfarin therapy does not increase risk of symptomatic intracerebral hemorrhage in eligible patients after intravenous thrombolysis. Arch Neurol 2011; 68: 135.
9. Prabhakaran S, Rivolta J, Vieira JR, et al. Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2010; 67: 559-563.
10. Ruecker M, Matosevic B, Willeit P, et al. Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis. Neurology 2012; 79: 31-38.
11. Miedema I, Gosselt A, de Keyser J, et al. Prior anticoagulant therapy, subtherapeutic international normalized ratio and thrombolytic therapy in acute ischemic stroke. Int J Stroke 2011; 6: 568-569.
12. Matute MC, Masjuan J, Egido JA, et al. Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants. Cerebrovasc Dis 2012; 33: 231-239.
13. Meretoja A, Putaala J, Tatlisumak T, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 2010; 41: 1450-1458.
14. Vergouwen MD, Casaubon LK, Swartz RH, et al. Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator. Stroke 2011; 42: 1041-1045.
15. Miedema I, Luijckx GJ, De Keyser J, et al. Thrombolytic therapy for ischaemic stroke in patients using warfarin: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2012; 83: 537-540.
16. Frank B, Grotta JC, Alexandrov AV, et al for the VISTA Collaborators. Thrombolysis in stroke despite contraindications or warnings? Stroke 2013; 44: 727-733.
17. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283: 1145-1150.
18. Brunner F, Tomandl B, Schröter A, et al. Hemorrhagic complications after systemic thrombolysis in acute stroke patients with abnormal baseline coagulation. Eur J Neurol 2011; 18: 1407-1411.
19. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282.
20. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372: 1303-1309.
21. Mazya M, Egido JA, Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: Safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke 2012; 43: 1524-1531.
22. Bastianello S, Pierallini A, Colonnese C, et al. Hyperdense middle cerebral artery CT sign. Comparison with angiography in the acute phase of ischemic supratentorial infarction. Neuroradiology 1991; 33: 207-211.
23. Leys D, Pruvo JP, Godefroy O, et al. Prevalence and significance of hyperdense middle cerebral artery in acute stroke. Stroke 1992; 23: 317-324.
24. Kharitonova T, Thorén M, Ahmed N, et al. Disappearing hyperdense middle cerebral artery sign in ischemic stroke patients treated with intravenous thrombolysis: clinical course and prognostic significance. J Neurol Neurosurg Psychiatry 2009; 80: 273-278.
25. Wahlgren N, Ahmed A, Eriksson N, et al, for the SITS-MOST investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS-MOST). Stroke 2008; 39: 3316-3322.
26. Strbian D, Sairanen T, Meretoja A, et al, for the Helsinki Stroke Thrombolysis Registry Group. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology 2011; 77: 341-348.
27. Seet RC, Rabinstein AA,. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. Cerebrovasc Dis 2012; 34: 106-114.
28. Gumbinger C, Gruschka P, Böttinger M, et al. Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage. Stroke 2012; 43: 240-242.
29. Kharitonova T, Ahmed N, Thorén M, et al. Hyperdense middle cerebral artery sign on admission CT scan-prognostic significance for ischaemic stroke patients treated with intravenous thrombolysis in the safe implementation of thrombolysis in Stroke International Stroke Thrombolysis Register. Cerebrovasc Dis 2009; 27: 51-59.